Differences

This shows you the differences between two versions of the page.

--- endocrine:sglt2:start [2026/02/13 00:06] – andrew2393cns
+++ endocrine:sglt2:start [2026/02/13 00:07] (current) – [SGLT2 vs Other Metabolic Agents] andrew2393cns
@@ Line 39: / Line 39: @@
 ===== Available Agents =====
-• [[endocrine:sglt2:dapagliflozin|Dapagliflozin]]
+  * • [[endocrine:sglt2:dapagliflozin|Dapagliflozin]]
-• [[endocrine:sglt2:empagliflozin|Empagliflozin]]
+  * • [[endocrine:sglt2:empagliflozin|Empagliflozin]]
-• [[endocrine:sglt2:sotagliflozin|Sotagliflozin]]
+  * • [[endocrine:sglt2:sotagliflozin|Sotagliflozin]]
 All share similar cardiorenal benefits.
@@ Line 118: / Line 118: @@
 SGLT2 inhibitors:
-• Strong heart failure benefit
+  * • Strong heart failure benefit
-• Strong renal protection
+  * • Strong renal protection
-• Mild diuretic effect
+  * • Mild diuretic effect
 GLP-1 receptor agonists:
-• Greater weight loss
+  * • Greater weight loss
-• Stronger atherosclerotic benefit
+  * • Stronger atherosclerotic benefit
 --------------------------------------------------------------------